Trials / Completed
CompletedNCT00645892
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adalimumab | OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24 |
| DRUG | placebo for adalimumab | OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24 |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2004-09-01
- First posted
- 2008-03-28
- Last updated
- 2008-03-28
Source: ClinicalTrials.gov record NCT00645892. Inclusion in this directory is not an endorsement.